Clinical Trial Detail

NCT ID NCT01528345
Title Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant + Dovitinib

Fulvestrant

Age Groups: adult

Additional content available in CKB BOOST